Trial · NCT01801358
Adverse events618
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 618
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | HYPERTENSION | Vascular disorders | Phase Ib: AEB071 150 mg Bid + MEK162 45 mg Bid (SS) | 1 | 6 | 1 |
| other | HYPERTENSION | Vascular disorders | Phase Ib: AEB071 200 mg Bid + MEK162 45 mg Bid (SS) | 0 | 6 | 0 |
| other | HYPERTENSION | Vascular disorders | Phase Ib: AEB071 300 mg Bid + MEK162 30 mg Bid (SS) | 1 | 6 | 1 |
| other | HYPERTENSION | Vascular disorders | Phase Ib: AEB071 300 mg Bid + MEK162 45 mg Bid (SS) | 0 | 6 | 0 |
| other | HYPERTENSION | Vascular disorders | Phase Ib: AEB071 350 mg Bid + MEK162 30 mg Bid (SS) | 0 | 6 | 0 |
| other | HYPERTENSION | Vascular disorders | Phase Ib: AEB071 400 mg Bid + MEK162 30 mg Bid (SS) | 3 | 8 | 3 |
| other | TUMOUR PAIN | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Phase Ib: AEB071 150 mg Bid + MEK162 45 mg Bid (SS) | 1 | 6 | 1 |
| other | TUMOUR PAIN | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Phase Ib: AEB071 200 mg Bid + MEK162 45 mg Bid (SS) | 0 | 6 | 0 |
| other | TUMOUR PAIN | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Phase Ib: AEB071 300 mg Bid + MEK162 30 mg Bid (SS) | 0 | 6 | 0 |
| other | TUMOUR PAIN | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Phase Ib: AEB071 300 mg Bid + MEK162 45 mg Bid (SS) | 1 | 6 | 1 |
| other | TUMOUR PAIN | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Phase Ib: AEB071 350 mg Bid + MEK162 30 mg Bid (SS) | 0 | 6 | 0 |
| other | TUMOUR PAIN | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Phase Ib: AEB071 400 mg Bid + MEK162 30 mg Bid (SS) | 0 | 8 | 0 |
| other | FATIGUE | General disorders | Phase Ib: AEB071 150 mg Bid + MEK162 45 mg Bid (SS) | 3 | 6 | 3 |
| other | FATIGUE | General disorders | Phase Ib: AEB071 200 mg Bid + MEK162 45 mg Bid (SS) | 4 | 6 | 4 |
| other | FATIGUE | General disorders | Phase Ib: AEB071 300 mg Bid + MEK162 30 mg Bid (SS) | 3 | 6 | 3 |
| other | FATIGUE | General disorders | Phase Ib: AEB071 300 mg Bid + MEK162 45 mg Bid (SS) | 3 | 6 | 3 |
| other | FATIGUE | General disorders | Phase Ib: AEB071 350 mg Bid + MEK162 30 mg Bid (SS) | 3 | 6 | 3 |
| other | FATIGUE | General disorders | Phase Ib: AEB071 400 mg Bid + MEK162 30 mg Bid (SS) | 5 | 8 | 5 |
| other | OEDEMA PERIPHERAL | General disorders | Phase Ib: AEB071 150 mg Bid + MEK162 45 mg Bid (SS) | 2 | 6 | 2 |
| other | OEDEMA PERIPHERAL | General disorders | Phase Ib: AEB071 200 mg Bid + MEK162 45 mg Bid (SS) | 2 | 6 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01801358/events